XML 44 R33.htm IDEA: XBRL DOCUMENT
v3.24.4

SHARE-BASED PAYMENTS | 6 Months Ended | 12 Months Ended
--- | --- | ---
Jun. 30, 2024 | Dec. 31, 2023
SHARE-BASED PAYMENTS |
| 17. | SHARE-BASED PAYMENTS
The issuance of warrants to the placement agent As mentioned in Note 16(a), in addition to fees and offering expenses paid in cash to the placement agent, the Group issued to the placement agent warrants to purchase an aggregate of up to five percent (5%) of the aggregate number of Shares sold in the Registered Offering (the “Placement Agent Warrants”). The Placement Agent Warrants shall generally be on the same terms and conditions as the Investors Warrants except that they will be exercisable at a price of $2.20 per share. The issuance of the agent warrants is an equity-settled share-based payment for professional services received from the placement agent. The Company recognized other capital reserves in an amount of CNY588 (US$82*), which represented the fair value of agent warrants as of issuance date. The fair value of services recorded is not used since it cannot be reliably estimated. The amount was allocated to the issuance of the common shares and investor warrants according to their relative fair values at the date of issuance and CNY383 (US$53*) and CNY205 (US$29*) were charged to share capital and administrative expenses, respectively. The fair value of the agent warrants is estimated at the issue date using a binomial lattice pricing model using significant observable inputs including underlying spot price of the Company's ordinary shares, exercise price, time to expiration, risk-free rate and equity volatility, etc. *As the changes in equity from this private placement transaction are dominated in US$, all the amount in US$ of this disclosure paragraph are actual transaction amount and corresponding amount in CNY were translated from US$ at the applicable exchange rate of the transaction date, February 21, 2024. |
26. |  | SHARE-BASED PAYMENTS
Warrants to the placement agent The Company issued and sold an aggregate of 3,960,000 of its common shares at a price of US$1.85 per share to certain institutional investors on January 22, 2021 through a private placement. In a concurrent private placement, the Company issued the warrants:
(i) |  | to the institutional investors (the “investor warrants”), which gave the right to purchase an aggregate of 1,584,000 common shares of the Company with an exercise price of US$2.35 per share. The investor warrants are exercisable up to three years after January 22, 2021. The Company recognized the investor warrants issued as derivative financial liabilities as the investors have the right to exercise their warrants on a cashless basis according to the agreement clause.
(ii) |  | to the placement agent (the “agent warrants”) as part of placement service fees, which gave the right to purchase an aggregate of 396,000 common shares with an exercise price of US$2.35 per share. The agent warrants are exercisable up to three years after July 21, 2021. There are no cash settlement alternatives. The Group does not have a past practice of cash settlement for the warrants. The Group accounts for the warrants as equity-settled share-based payment.
The fair value of the agent warrants is estimated at the grant date using a binomial option pricing model. The amount was allocated to the issuance of the common shares and the investor warrants according to their fair value at the date of issuance, and CNY1,862 (US$287*) and CNY449 (US$70*) were charged to share capital and administrative expenses respectively.
* | As the changes in equity from this private placement transaction are denominated in US$, all the amounts in US$ in this disclosure paragraph are actual transaction amounts and the corresponding amounts in CNY were translated from US$ at the applicable exchange rate on the transaction date, January 22, 2021.
Share options On July 14, 2022, the Board of Directors of the Company approved to grant option awards for an aggregate of 8,100,000 common shares, without par value, of the Company (the “share options”) to certain individuals under the China Natural Resources, Inc. 2014 Equity Compensation Plan for certain strategic consultant services. The share options vested immediately upon grant and are exercisable up to three years from July 19, 2022. The exercise price for the options is $0.623 per share. The fair value of the share options is estimated at the grant date using a binomial option pricing model, taking into account the terms and conditions on which the share options were granted. The Group accounts for share options 2022 as an equity-settled share-based payment and recognize administrative expenses associated with the consultant service reward with a corresponding increase in equity. Share-based payment On June 26, 2023, the Board of Directors of the Company approved to grant share-based payment of 180,000 common shares for consultant’s service between June 26 to December 25, 2023. As the Group cannot measure reliably the fair value of the service received, it is based on the fair value of the common shares granted measured over the period the services is received. The Group recognized administrative expenses associated with the consultant service reward with a corresponding increase in equity using the average fair value of the common shares over the service period. The 180.000 common shares were vested and issued in 2023.
(a) |  | Expense arising from share-based payment transactions
The expense recognized during the year for above share-based payments is shown in the following table:
Schedule of expense arising from share-based payments |  |  |  |  |  |  |  |  |  |  |  |
|  | Year Ended December 31, |
|  | 2021 |  |  | 2022 |  |  | 2023 |  |  | 2023 |
|  | CNY |  |  | CNY |  |  | CNY |  |  | US$ |
Issuance expense related to agent warrants |  |  | 447 |  |  |  | — |  |  |  | — |  |  |  | — |
Consultants share option expense (Note 5) |  |  | — |  |  |  | 16,152 |  |  |  | — |  |  |  | — |
Consultants share-based payment expense (Note 5) |  |  | — |  |  |  | — |  |  |  | 3,074 |  |  |  | 435 |
Total |  |  | 447 |  |  |  | 16,152 |  |  |  | 3,074 |  |  |  | 435 |
(b) |  | Movements during the year
The following table illustrates the number of, and movements in, agent warrants during the year:
Schedule of agent warrants |  |  |  |  |  |
|  | Number of shares |  |  | Exercise price per share |
|  |  |  |  |  |  | US$ |
Outstanding at January, 2021 |  |  | — |  |  |  | — |
Granted during the year |  |  | 396,000 |  |  |  | 2.35 |
Outstanding as of December 31, 2021 |  |  | 396,000 |  |  |  | 2.35 |
Outstanding as of December 31, 2022 |  |  | 396,000 |  |  |  | 0.623 | *
Effect of Five-to-One Share Combination (Note 24) |  |  | (316,800 | ) |  |  | — |
Outstanding as of December 31, 2023 |  |  | 79,200 |  |  |  | 3.115 | **
The remaining contractual life for the agent warrants as of December 31, 2023 and 2022, were 0.06 years and 1.06 years, respectively.
* |  | The exercise price was revised to $0.623 per share in July, 2022.
** |  | The exercise price was revised to $3.115 per share in March, 2023.
The following table illustrates the number of, and movements in share options during the year:
Schedule of share options |  |  |  |  |  |
|  | Number of shares |  |  | Exercise price per share |
|  |  |  |  |  |  | US$ |
Outstanding as of January, 2021 and December 31, 2021 |  |  | — |  |  |  | — |
Granted during the year |  |  | 8,100,000 |  |  |  | 0.623 |
Outstanding as of December 31, 2022* |  |  | 8,100,000 |  |  |  | 0.623 |
Granted during the year |  |  | — |  |  |  | — |
Effect of Five-to-One Share Combination (Note 24) |  |  | (6,480,000 | ) |  |  | — |
Outstanding as of December 31, 2023 |  |  | 1,620,000 |  |  |  | 3.115 |
* |  | The share option numbers above are before giving effect to the Share Combination which became effective on April 3, 2023. Refer to Note 24 for further details.
The remaining contractual life for the share option as of December 31, 2023 and 2022, were 1.53 years and 2.53 years, respectively.
(c) |  | Inputs to the models
The following tables list the inputs to the models used for agent warrants and share options for the years ended December 31, 2021 and 2022, respectively:
Schedule of inputs to the models for fair value |  |  |  |  |  |
|  | Agent warrants |  |  | Share options |
|  |  | 2021 |  |  |  | 2022 |
Fair value at the measurement date (US$) |  |  | 70 |  |  |  | 2,400 |
Fair value at the measurement date (CNY) |  |  | 449 |  |  |  | 16,209 |
Expected volatility (%) |  |  | 93.67 |  |  |  | 93.50 |
Risk-free interest rate (%) |  |  | 0.19 |  |  |  | 3.16 |
Expected life (years) |  |  | 2.50 |  |  |  | 3 |
Share price (US$) |  |  | 0.901 |  |  |  | 0.623 |
The expected life of the agent warrants and share options is based on historical data and current expectations and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility over a period similar to the life of the options is indicative of future trends, which may not necessarily be the actual outcome.

X
- Definition The disclosure of the general terms and conditions of share-based payment arrangements. [Refer: Share-based payment arrangements [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2023-01-01 -Paragraph 45 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration